- Deutsche's Robyn Karnauskas is apparently out pounding the table on Biogen (BIIB +1.3%).
- Investors have a "rare buying opportunity" in the shares which she says could hit $400 or more each.
- Color: "We see BIIB likely to return ~50% cash back to shareholders in coming years. We model $8.5B by 2017 vs. street ~$2B."